IP Divisions In Indian Courts: Will Pharma See Expediated Adjudication?
Executive Summary
A second court in India establishes an intellectual property division to consider IPR matters and notifies rules following the dissolution of the Intellectual Property Appellate Board in 2021. Legal experts outline what that may mean for the efficiency and quality of IPR adjudications.
You may also be interested in...
India Biosimilar Cetuximab Go-Ahead: Merck KGaA Wants Data In Public Domain
Merck KGaA calls for data on Indian firm Enzene’s biosimilar cetuximab to be made available in the public domain, citing the Helsinki Declaration.
Heat On E-Pharmacies In India -The Shape Of Things To Come
India is expected to rein in the ‘unfettered’ run of e-pharmacies, a segment where top Indian conglomerates and Amazon have made strides, with pharma intertwined having tapped into these platforms. Scrip speaks to experts on areas of concern including prescription ‘workarounds’, supply chain transparency and data privacy where more oversight is called for amid the evolving regulatory landscape.
Pendulum Swings Again: Entresto Patent In India Restored, For Now
Patent pertaining to Novartis’s Entresto re-instated for now in India after a two-judge bench stays a previous order that set aside the grant of the patent. Will that put Indian firms that launched generic versions of the heart failure therapy at risk of infringement in the interim?